Abstract
Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) is a systemic disorder of mineral and bone metabolism that occurs in Chronic Kidney Disease (CKD). In addition to abnormalities in serum calcium (Ca) and phosphate (P) profile, CKD-MBD is characterized by abnormalities of bone turnover, mineralization, volume and growth as well as vascular calcification (VC). Indeed, the co-localization of bone markers such as Osteopontin, Alkaline Phosphatase and Osteocalcin along with osteoblast-like cells in the contest of the arterial wall of uremic patients, indicate that VC is an active biological process with peculiar analogies with bone mineralization. Thus, VC represents a plausible link between Ca and P derangements and the increased mortality associated with CKD-MBD. The process of VC starts in early stages of CKD and patients with CKD-3, -4 and -5 not undergoing haemodialysis may present a significant burden of calcification in the coronaries. Considering that presence and extent of VC in CKD portend poor prognosis, many efforts have been made to shed light on this complicated phenomenon to prevent VC deposition and progression. Indeed, careful control of calcium load, serum P and parathyroid hormone along with the use of calcium-free P binders and vitamin D analogs represent our current armamentarium to improve quality of life and reduce mortality in CKD. We herein summarize the current understanding and evidence supporting strategies available for VC treatment.
Keywords: Vascular calcification, mortality, mineral metabolism abnormalities, treatment
Current Vascular Pharmacology
Title: Arterial Accelerated Aging in Dialysis Patients: The Clinical Impact of Vascular Calcification
Volume: 7 Issue: 3
Author(s): Diego Brancaccio, Antonio Bellasi, Mario Cozzolino, Andrea Galassi and Maurizio Gallieni
Affiliation:
Keywords: Vascular calcification, mortality, mineral metabolism abnormalities, treatment
Abstract: Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) is a systemic disorder of mineral and bone metabolism that occurs in Chronic Kidney Disease (CKD). In addition to abnormalities in serum calcium (Ca) and phosphate (P) profile, CKD-MBD is characterized by abnormalities of bone turnover, mineralization, volume and growth as well as vascular calcification (VC). Indeed, the co-localization of bone markers such as Osteopontin, Alkaline Phosphatase and Osteocalcin along with osteoblast-like cells in the contest of the arterial wall of uremic patients, indicate that VC is an active biological process with peculiar analogies with bone mineralization. Thus, VC represents a plausible link between Ca and P derangements and the increased mortality associated with CKD-MBD. The process of VC starts in early stages of CKD and patients with CKD-3, -4 and -5 not undergoing haemodialysis may present a significant burden of calcification in the coronaries. Considering that presence and extent of VC in CKD portend poor prognosis, many efforts have been made to shed light on this complicated phenomenon to prevent VC deposition and progression. Indeed, careful control of calcium load, serum P and parathyroid hormone along with the use of calcium-free P binders and vitamin D analogs represent our current armamentarium to improve quality of life and reduce mortality in CKD. We herein summarize the current understanding and evidence supporting strategies available for VC treatment.
Export Options
About this article
Cite this article as:
Brancaccio Diego, Bellasi Antonio, Cozzolino Mario, Galassi Andrea and Gallieni Maurizio, Arterial Accelerated Aging in Dialysis Patients: The Clinical Impact of Vascular Calcification, Current Vascular Pharmacology 2009; 7 (3) . https://dx.doi.org/10.2174/157016109788340730
DOI https://dx.doi.org/10.2174/157016109788340730 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mst1: Function and Mechanism in Brain and Myocardial Ischemia Reperfusion Injury
Current Neuropharmacology Ambulatory Blood Pressure and Diabetes: Targeting Nondipping
Current Diabetes Reviews The Impact of Type 2 Diabetes on Women’s Health and Well-being During Their Reproductive Years: A Mixed-methods Systematic Review
Current Diabetes Reviews Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
Current Pharmaceutical Design The Critical Roles of HSC70 in Physiological and Pathological Processes
Current Pharmaceutical Design Beta-Adrenergic Antagonists: Indications and Potential Immunomodulatory Side Effects in the Critically Ill
Current Medicinal Chemistry Tackling Cardiovascular Risk: New Evidence from Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Inhibition of Early Upstream Events in Prodromal Alzheimer’s Disease by Use of Targeted Antioxidants
Current Aging Science Different Lifestyles in Young Women From Urban and Rural Areas May Explain Different Cardiovascular Risk
Vascular Disease Prevention (Discontinued) Improvement of Bioactive Potential of Canavalia Beans of Coastal Sand Dunes by Solid-Substrate Fermentation Using Rhizopus oligosporus
Current Nutrition & Food Science Complications of the Chest Wall and the Respiratory System After Surgery and Functional Performance
Current Respiratory Medicine Reviews A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews Ruthenium as an Effective Nitric Oxide Scavenger
Current Topics in Medicinal Chemistry Epidemiology and Costs of Hypertension-related Disorders
Current Pharmaceutical Design Changes in Serum Nampt Levels and Its Significances in Diabetic Nephropathy Patients-The Potential Role of Nampt in T2DM with Diabetic Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review
Current Drug Safety Conditional Cardiac Overexpression of S100A6 Attenuates Myocyte Hypertrophy and Apoptosis Following Myocardial Infarction
Current Pharmaceutical Design Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology Prevention and Treatment of Alzheimer Disease and Aging: Antioxidants
Mini-Reviews in Medicinal Chemistry